2023
1312. Incidence and Microbiology of Prosthetic Joint Infection According to Time Following Total Knee Arthroplasty: A Retrospective Cohort Study Among US Veterans
Weinstein E, Re V, Stephens-Shields A, Newcomb C, Silibovsky R, Nelson C, O’Donnell J, Glaser L, Hsieh E, Hanberg J, Akgün K, Tate J, King J. 1312. Incidence and Microbiology of Prosthetic Joint Infection According to Time Following Total Knee Arthroplasty: A Retrospective Cohort Study Among US Veterans. Open Forum Infectious Diseases 2023, 10: ofad500.1151. PMCID: PMC10678406, DOI: 10.1093/ofid/ofad500.1151.Peer-Reviewed Original ResearchLate prosthetic joint infectionsPrimary total knee arthroplastyProsthetic joint infectionTotal knee arthroplastyIncidence rate ratiosElective primary total knee arthroplastyJoint infectionKnee arthroplastyIncidence rateChi-squared testGram-negative organismsCumulative incidenceConfidence intervalsIncidence of PJIMicrobiology dataEarly prosthetic joint infectionKaplan-Meier failure curvesCulture-negative prosthetic joint infectionPrimary TKA surgeryRetrospective cohort studyKaplan-Meier methodPearson's chi-squared testGrant/research supportOverall study periodIncident hospitalization
2011
Adult glioblastoma multiforme survival in the temozolomide era: A population‐based analysis of Surveillance, Epidemiology, and End Results registries
Darefsky AS, King JT, Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: A population‐based analysis of Surveillance, Epidemiology, and End Results registries. Cancer 2011, 118: 2163-2172. PMID: 21882183, PMCID: PMC3235223, DOI: 10.1002/cncr.26494.Peer-Reviewed Original ResearchConceptsHazard ratioTemozolomide eraMultivariate-adjusted hazard ratiosEnd Results Program databaseKaplan-Meier methodPopulation-based surveillanceTwo-year survivalAge-stratified analysisConfidence intervalsPopulation-based analysisAge 20 yearsProportional hazards modelProgressive decreaseTemozolomide useOlder patientsSurgical resectionSurvival improvementTreatment advancesProgram databaseGBM patientsHazards modelGBM treatmentAge 20Age groupsGlioblastoma multiforme survival